Jong Sung Koh

This inventor holds 19 USPTO granted patents, plus 5 CIPO patents and 8 EPO patents, primarily in Kinase Inhibitors. Top assignees: Lg Chemical Ltd., Genosco, Oscotec Inc.. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jong Sung Koh. Retrieved from https://idiyas.com/inventor/jong-sung-koh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19

% Patents Active = 89.5

CIPO Patents = 5

EPO Patents = 8 (Patent Applications = 3)

Average Co-Inventor Count = 9.2

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Youseong-ku, KR (2001)
Taejon, KR (2002)
Daejeon, KR (1996 - 2011)
Seoul, KR (1990 - 2014)
Buchun, KR (2014)
Gyeonggi-Do, KR (2014 - 2017)

Company Filing History:

Korea Advanced Institute of Science and Technology

patents

7. 1 out of 75

Lg Life Sciences, Limited

patents

where one patent can have more than one assignee

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

EGFR Mutant Kinase

SYK Inhibitors

FLT3 Inhibitors

Dipeptidyl Peptidase-IV

Farnesyl Transferase

Imidazole Derivatives

HIV Protease Inhibitors

Pyrimidine Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50528 - Compounds and compositions for modulating EGFR mutant kinase activities (2025-08-12),

2. 9593098 - Compounds and compositions for modulating EGFR mutant kinase activities (2017-03-14),

3. 9212178 - Substituted pyrimidine compounds and their use as SYK inhibitors (2015-12-15),

4. 8877763 - Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors (2014-11-04),

5. 8871778 - Substituted pyrimidine compounds and their use as SYK inhibitors (2014-10-28),

6. 8629132 - Kinase inhibitors (2014-01-14),

7. 8404677 - Kinase inhibitors (2013-03-26),

8. 7879848 - Dipeptidyl Peptidase-IV inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent (2011-02-01),

9. 6518429 - Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof (2003-02-11),

10. 6472526 - Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof (2002-10-29),

11. 6436960 - Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof (2002-08-20),

12. 6384061 - Hydantoin compounds and methods related thereto (2002-05-07),

13. 6268363 - Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof (2001-07-31),

14. 5773468 - Irreversible HIV protease inhibitor having an anti-aids activity and (1998-06-30),

15. 5763631 - Irreversible HIV protease inhibitors, intermediates, compositions and (1998-06-09),

Title: Innovations of Jong Sung Koh: A Pioneer in Pharmaceutical Development

Introduction: Jong Sung Koh is a distinguished inventor based in Daejeon, South Korea, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 12 patents, he has established himself as a leader in the development of compounds with innovative therapeutic applications.

Latest Patents: One of Jong Sung Koh's latest inventions includes novel compounds that inhibit Dipeptidyl Peptidase-IV (DPP-IV), which are important in managing conditions like diabetes. These compounds, particularly those of a specific chemical formula, demonstrate excellent inhibitory activity and the potential for being developed into effective pharmaceutical compositions. Additionally, he has developed imidazole derivatives that exhibit inhibitory activity against farnesyl transferase. His work also discloses intermediate compounds and processes vital for the preparation of these innovative imidazole derivatives, further expanding the landscape of pharmaceutical development.

Career Highlights: Jong Sung Koh's career is marked by significant milestones, particularly his tenure with well-regarded companies such as LG Chemical Ltd. and Lucky Limited. Through his work, he has demonstrated an unwavering commitment to advancing pharmaceutical science and improving patient care through innovative drug development.

Collaborations: Throughout his career, Jong Sung Koh has collaborated with notable colleagues, including Hyun Il Lee and Jong Hyun Kim. These partnerships have fostered a multidisciplinary approach to his research and have profoundly contributed to the successful development of his patented compounds.

Conclusion: Jong Sung Koh stands out as a prolific inventor whose work in pharmaceuticals is characterized by innovation and dedication. His latest patents reflect his commitment to developing compounds with substantial therapeutic potential, positioning him as a key contributor to advancements in medical science. As research continues to evolve, his inventions are likely to play a critical role in shaping future treatments and healthcare solutions.

Profile summary based on public USPTO records.